The use of incretins and fractures - a meta-analysis on population-based real life data

Johanna H. M. Driessen; Frank de Vries; Hein van Onzenoort; Nicholas C. Harvey; Cees Neef; Joop P. W. van den Bergh; Peter Vestergaard; Ronald M. A. Henry

doi:10.1111/bcp.13167

The use of incretins and fractures - a meta-analysis on population-based real life data

Johanna H. M. Driessen, Frank de Vries^*, Hein van Onzenoort, Nicholas C. Harvey, Cees Neef, Joop P. W. van den Bergh, Peter Vestergaard, Ronald M. A. Henry

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

23 Citations (Web of Science)

Abstract

The aim of the present study was to estimate the effect of incretins on fracture risk in the real-world situation by meta-analysis of the available population-based cohort data. Pubmed and Embase were searched for original articles investigating use of incretin agents, and fracture risk up to December 2015. Adjusted results were extracted and pooled by use of generic inverse variance methods, assuming a random-effects model. Neither current dipeptidyl peptidase 4-inhibitor use nor current glucagon-like peptide 1 receptor agonist use was associated with a decreased risk of fracture: pooled relative risk (pooled RR [95% confidence interval]: 1.02 [0.91-1.13] and 1.03 [0.87-1.22]), respectively. This meta-analysis demonstrated that current use of incretin agents, was not associated with decreased fracture risk. Our findings show the value of representative real-world populations, and the risks associated with suggesting benefits for medications on the basis of safety reporting in randomized controlled trials.

Original language	English
Pages (from-to)	923-926
Number of pages	4
Journal	British Journal of Clinical Pharmacology
Volume	83
Issue number	4
DOIs	https://doi.org/10.1111/bcp.13167
Publication status	Published - Apr 2017

Keywords

dipeptidyl peptidase 4-inhibitors
fracture
glucagon-like peptide 1-receptor agonists
incretin agents
meta-analysis
PEPTIDE-1 RECEPTOR AGONISTS
DIPEPTIDYL PEPTIDASE-4 INHIBITORS
RANDOMIZED CLINICAL-TRIALS
ANTI-HYPERGLYCEMIC DRUGS
BONE-FRACTURES
RISK

Access to Document

10.1111/bcp.13167

Cite this

@article{3ac999f93ac24e67aa65f760c6caa8d8,

title = "The use of incretins and fractures - a meta-analysis on population-based real life data",

abstract = "The aim of the present study was to estimate the effect of incretins on fracture risk in the real-world situation by meta-analysis of the available population-based cohort data. Pubmed and Embase were searched for original articles investigating use of incretin agents, and fracture risk up to December 2015. Adjusted results were extracted and pooled by use of generic inverse variance methods, assuming a random-effects model. Neither current dipeptidyl peptidase 4-inhibitor use nor current glucagon-like peptide 1 receptor agonist use was associated with a decreased risk of fracture: pooled relative risk (pooled RR [95% confidence interval]: 1.02 [0.91-1.13] and 1.03 [0.87-1.22]), respectively. This meta-analysis demonstrated that current use of incretin agents, was not associated with decreased fracture risk. Our findings show the value of representative real-world populations, and the risks associated with suggesting benefits for medications on the basis of safety reporting in randomized controlled trials.",

keywords = "dipeptidyl peptidase 4-inhibitors, fracture, glucagon-like peptide 1-receptor agonists, incretin agents, meta-analysis, PEPTIDE-1 RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE-4 INHIBITORS, RANDOMIZED CLINICAL-TRIALS, ANTI-HYPERGLYCEMIC DRUGS, BONE-FRACTURES, RISK",

author = "Driessen, {Johanna H. M.} and {de Vries}, Frank and {van Onzenoort}, Hein and Harvey, {Nicholas C.} and Cees Neef and {van den Bergh}, {Joop P. W.} and Peter Vestergaard and Henry, {Ronald M. A.}",

year = "2017",

month = apr,

doi = "10.1111/bcp.13167",

language = "English",

volume = "83",

pages = "923--926",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - The use of incretins and fractures - a meta-analysis on population-based real life data

AU - Driessen, Johanna H. M.

AU - de Vries, Frank

AU - van Onzenoort, Hein

AU - Harvey, Nicholas C.

AU - Neef, Cees

AU - van den Bergh, Joop P. W.

AU - Vestergaard, Peter

AU - Henry, Ronald M. A.

PY - 2017/4

Y1 - 2017/4

N2 - The aim of the present study was to estimate the effect of incretins on fracture risk in the real-world situation by meta-analysis of the available population-based cohort data. Pubmed and Embase were searched for original articles investigating use of incretin agents, and fracture risk up to December 2015. Adjusted results were extracted and pooled by use of generic inverse variance methods, assuming a random-effects model. Neither current dipeptidyl peptidase 4-inhibitor use nor current glucagon-like peptide 1 receptor agonist use was associated with a decreased risk of fracture: pooled relative risk (pooled RR [95% confidence interval]: 1.02 [0.91-1.13] and 1.03 [0.87-1.22]), respectively. This meta-analysis demonstrated that current use of incretin agents, was not associated with decreased fracture risk. Our findings show the value of representative real-world populations, and the risks associated with suggesting benefits for medications on the basis of safety reporting in randomized controlled trials.

AB - The aim of the present study was to estimate the effect of incretins on fracture risk in the real-world situation by meta-analysis of the available population-based cohort data. Pubmed and Embase were searched for original articles investigating use of incretin agents, and fracture risk up to December 2015. Adjusted results were extracted and pooled by use of generic inverse variance methods, assuming a random-effects model. Neither current dipeptidyl peptidase 4-inhibitor use nor current glucagon-like peptide 1 receptor agonist use was associated with a decreased risk of fracture: pooled relative risk (pooled RR [95% confidence interval]: 1.02 [0.91-1.13] and 1.03 [0.87-1.22]), respectively. This meta-analysis demonstrated that current use of incretin agents, was not associated with decreased fracture risk. Our findings show the value of representative real-world populations, and the risks associated with suggesting benefits for medications on the basis of safety reporting in randomized controlled trials.

KW - dipeptidyl peptidase 4-inhibitors

KW - fracture

KW - glucagon-like peptide 1-receptor agonists

KW - incretin agents

KW - meta-analysis

KW - PEPTIDE-1 RECEPTOR AGONISTS

KW - DIPEPTIDYL PEPTIDASE-4 INHIBITORS

KW - RANDOMIZED CLINICAL-TRIALS

KW - ANTI-HYPERGLYCEMIC DRUGS

KW - BONE-FRACTURES

KW - RISK

U2 - 10.1111/bcp.13167

DO - 10.1111/bcp.13167

M3 - Article

C2 - 27780288

SN - 0306-5251

VL - 83

SP - 923

EP - 926

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 4

ER -